The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma
Open accessAbstract
Pancreatic ductal adenocarcinoma (PDAC), one of the most lethal neoplasms, is characterized by an expanded stroma with marked fibrosis (desmoplasia). We previously generated pancreas epithelium-specific TGF-β receptor type II (Tgfbr2) knockout mice in the context of Kras activation (mice referred to herein as Kras+Tgfbr2KO mice) and found that they developed aggressive PDAC that recapitulated the histological manifestations of the human disease. The mouse PDAC tissue showed strong expression of connective tissue growth factor (Ctgf), a profibrotic and tumor-promoting factor, especially in the tumor-stromal border area, suggesting an active tumor-stromal interaction. Here we show that the PDAC cells in Kras+Tgfbr2KO mice secreted much higher levels of several Cxc chemokines compared with mouse pancreatic intraepithelial neoplasia cells, which are preinvasive. The Cxc chemokines induced Ctgf expression in the pancreatic stromal fibroblasts, not in the PDAC cells themselves. Subcutaneous grafting studies revealed that the fibroblasts enhanced growth of PDAC cell allografts, which was attenuated by Cxcr2 inhibition. Moreover, treating the Kras+Tgfbr2KO mice with the CXCR2 inhibitor reduced tumor progression. The decreased tumor progression correlated with reduced Ctgf expression and angiogenesis and increased overall survival. Taken together, our data indicate that tumor-stromal interactions via a Cxcr2-dependent chemokine and Ctgf axis can regulate PDAC progression. Further, our results suggest that inhibiting tumor-stromal interactions might be a promising therapeutic strategy for PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, data from various mouse models indicate that disrupting the CXCR1/2–MDSC axis in tumours is therapeutically efficacious across a wide variety of solid cancers166–172.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [169]
In the citing paper
“Moreover, the important role of CXCR2 in pancreatic adenocarcinoma models (Ijichi et al., 2011) and of S100A8/9 in colorectal cancer (Ichikawa et al., 2011) suggest that the relevance of targeting the CXCL1/2–S100A8/9 axis may extend beyond breast cancer.”
From A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis (2012) · cites this paper as Ijichi et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1256 · Cited by 3,413
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis
Condeelis, J. S., & Pollard, J. W. (2006) · Cell · doi:10.1016/j.cell.2006.01.007 · Cited by 2,677
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Käkönen, S.-M., Cordon‐Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,605
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Self-citationAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasPreprint
Jackson, E. L., Willis, N. A., Mercer, K. L., Bronson, R. T., Crowley, D. G., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,927
Flagged first, then by citations
Research works printed but not linked: 5
- Rozenblum, 1997, Cancer Res., 57, 1731
- Venkatasubbarao, 2000, Anticancer Res., 20, 43
- Fujioka, 2003, Clin Cancer Res., 9, 346
- Shier, 1999, Anticancer Res., 19, 4969
- Weidner, 1995, Am J Pathol., 147, 9
Cited by
Sorted by citations
Items 201–256 of 256
Molecular Phenotypes of Endothelial Cells in Malignant Tumors
Milošević, V., Edelmann, R. J., Fosse, J. H., Östman, A., & Akslen, L. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_3 · Cited by 7
Barrambana, S., Zamorano-Domínguez, E., Liaki, V., & Guerra, C. E. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115652 · Cited by 8
Ijichi, H. (2022) · Cancers · doi:10.3390/cancers14194880 · Cited by 6
Self-citationNghiem, E., Friedman, B., Srivastava, N., Takchi, A., Mohammadi, M., Dedushi, D., Edelmann, W., Kuang, C., & Bteich, F. (2025) · Pharmaceuticals · doi:10.3390/ph18081160 · Cited by 8
Zhou, W., & Zhang, W. (2022) · BMC Cancer · doi:10.1186/s12885-022-09790-z · Cited by 6
Hung, J. S.-C., Perez, S. M., Dasa, S. S. K., Hall, S. P., Heckert, D. B., Murphy, B. P., Crawford, H. C., Kelly, K. A., & Brinton, L. T. (2023) · Pharmaceuticals · doi:10.3390/ph16030389 · Cited by 6
MMTV-NeuT/ATTAC mice: a new model for studying the stromal tumor microenvironment
Yuan, H., Wang, X., Jin, L., Zhang, Q., Brandina, I., Alexandrov, I. M., & Glazer, R. I. (2018) · Oncotarget · doi:10.18632/oncotarget.24233 · Cited by 5
TLR4-Induced Inflammation Is a Key Promoter of Tumor Growth, Vascularization, and Metastasis
Ran, S., Bhattarai, N., Patel, R., & Volk-Draper, L. D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85195 · Cited by 6
The Versatile World of Inflammatory Chemokines in Cancer
Leibovich-Rivkin, T., Lebel-Haziv, Y., Lerrer, S., Weitzenfeld, P., & Ben‐Baruch, A. (2013) · Springer eBooks · doi:10.1007/978-94-007-6217-6_6 · Cited by 4
Abbas, S. M. (2013) · Surgical Oncology · doi:10.1016/j.suronc.2012.12.002 · Cited by 4
Mesenchymal stromal cells release CXCL1/2/8 and induce chemoresistance and macrophage polarizationPreprint
Couderc, B. C., Naour, A. L., Prat, M., Mével, R., Thibault, B., Lemaitre, L., Leray, H., Golzio, M., Lefèvre, L., Mery-Lamarche, E., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/482513 · Cited by 4
TGF-β as Tumor Suppressor: Lessons from Mouse Models
Valcourt, U., Vincent, D., & Bartholin, L. (2013) · Springer eBooks · doi:10.1007/978-4-431-54409-8_6 · Cited by 3
New frontier for epilepsy treatment through targeting cellular senescence
Bello, S. T., Rafe, M. R., & Huang, F. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111506 · Cited by 3
Kimura, G., Ijichi, H., Sano, M., Notoya, G., Miyabayashi, K., Takahashi, R., Kishikawa, T., & Mitsuhiro, F. (2025) · Scientific Reports · doi:10.1038/s41598-025-32222-4 · Cited by 2
Self-citationThe Significance of CXCL1 in Cancer: An Overview of Molecular Mechanisms
Korbecki, J., Bosiacki, M., Dzięciołowska-Baran, E., Pawlik, P., Lubkowski, M., Walaszek, I., & Barczak, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062693 · Cited by 2
Inflammatory Dysregulation and Cancer: From Molecular Mechanisms to Therapeutic Opportunities
Steele, C. W., Jamieson, N. B., & Carter, C. R. (2014) · Springer eBooks · doi:10.1007/978-94-017-9421-3_17 · Cited by 2
The Role of CXCR2 in Pancreatic Cancer Development and Progression
Purohit, A. (2015) · DigitalCommons@UNMC · Cited by 2
Novel Therapeutic Modalities for Metastatic Pancreatic Cancer
Bang, S. (2016) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2016.21.4.185 · Cited by 2
Li, X., Nania, S., Kleiter, I., Löhr, J.-M., & Heuchel, R. L. (2021) · Pancreas · doi:10.1097/mpa.0000000000001951 · Cited by 2
Wang, C., Zhang, Q., Li, Q., Wang, Y., & Chen, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-02768-w · Cited by 1
Chaudhary, S., Iniyan, A. M., Ganguly, K., Pothuraju, R., Wang, H., Cox, J. L., Lele, S. M., Nasser, M. W., Lakshmanan, I., Macha, M. A., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218269 · Cited by 1
From inflammation to malignancy: the dynamic evolution of cancer-associated fibroblasts in IBD-CRC
Naito, N., Kasashima, H., Fukuoka, T., Nakanishi, Y., Ohtani, N., & Maeda, K. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101310 · Cited by 1
Acuna, L., & Armando, J. (2013) · Cited by 1
Taucher, V., & Haybaeck, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-53661-3_5 · Cited by 1
Inverso, D., Tacconi, C., Ranucci, S., & Giovanni, M. D. (2024) · European Journal of Immunology · doi:10.1002/eji.202350870 · Cited by 1
Unlocking the Power of CXCR2 Inhibition to Overcome Gemcitabine Resistance in Pancreatic Cancer
Molczyk, C., Sturgeon, R., Saxena, S., Johnson, E., Bhatia, R., Bhyravbhatla, N., Kumar, S., Batra, S. K., & Singh, R. K. (2026) · FASEB BioAdvances · doi:10.1096/fba.2025-00265 · Cited by 1
Mouse Models of Pancreatic Cancer
Ostapoff, K. T., Dellinger, M. T., Awasthi, N., Brekken, R. A., & Schwarz, R. E. (2013) · Springer eBooks · doi:10.1007/978-94-007-7835-1_4 · Cited by 1
High CXCL6 drives matrix expression and correlate with markers of poor outcome in IPFPreprint
Bahudhanapati, H., Tan, J., Apel, R. M., Seeliger, B., Li, X., Chen, T., Sullivan, D. I., Sembrat, J., Rojas, M. M., Tabib, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.22.449424 · Cited by 1
Ciblage thérapeutique du microenvironnement tumoral : exemple du cancer du pancréas
Samain, R. (2014) · OpenGrey (Institut de l'Information Scientifique et Technique)
The role of chemokines in vertebrate physiology and disease: a concise review
Mahgoub, H. A. (2021) · Mansoura Veterinary Medical Journal · doi:10.21608/mvmj.2021.46848.1014
Yang, T., Deng, Z., Xu, L., Li, X., Tan, Y., Qian, Y., Lu, Y., Li, T. X., Yao, W., & Wang, J. (2021) · Research Square · doi:10.21203/rs.3.rs-921949/v1
II-J3-5 CYBEXにより測定した前十字靭帯再建術後の膝筋力の経時的変化
Yatsuka, T., 津村, 弘., 内納, 正., & 鳥巣, 岳. (1999)
Zhou, X., Xiao, F., Sugimoto, H., Li, B., McAndrews, K. M., & Kalluri, R. (2023) · doi:10.1158/0008-5472.c.6512667.v1
Physiological Changes in the Local Onco-Sphere: Angiogenesis
Saw, P. E., & Song, E. (2023) · Springer eBooks · doi:10.1007/978-981-99-1183-7_6
Ijichi, H., Kimura, G., Sano, M., Notoya, G., Miyabayashi, K., Takahashi, R., Kishikawa, T., & Fujishiro, M. (2024) · Research Square · doi:10.21203/rs.3.rs-5124479/v1
Self-citationCell of Origin and Mouse Models for Pancreatic Cancer
Means, A. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.04906-6
Cheng, Y., Mo, F., Li, Q., Han, X., Shi, H., Chen, S., Wei, Y., & Wei, X. (2021) · Figshare · doi:10.6084/m9.figshare.14370974
Cheng, Y., Mo, F., Li, Q., Han, X., Shi, H., Chen, S., Wei, Y., & Wei, X. (2021) · Figshare · doi:10.6084/m9.figshare.14370977
Cheng, Y., Mo, F., Li, Q., Han, X., Shi, H., Chen, S., Wei, Y., & Wei, X. (2021) · Figshare · doi:10.6084/m9.figshare.14370983
Cheng, Y., Mo, F., Li, Q., Han, X., Shi, H., Chen, S., Wei, Y., & Wei, X. (2021) · Figshare · doi:10.6084/m9.figshare.14370986
Cheng, Y., Mo, F., Li, Q., Han, X., Shi, H., Chen, S., Wei, Y., & Wei, X. (2021) · Figshare · doi:10.6084/m9.figshare.14370989
Cheng, Y., Mo, F., Li, Q., Han, X., Shi, H., Chen, S., Wei, Y., & Wei, X. (2021) · Figshare · doi:10.6084/m9.figshare.14370980
Etude de la reprogrammation métabolique de l' adénocarcinome canalaire pancréatique
Olivares, O. (2015) · theses.fr (ABES) · doi:10.70675/ef2c6a2czab6dz4a68z8004z1ade8605dadc
Akinsipe, T., Odewumi, C. O., Latinwo, L. M., Aghimien, O. O., Musa, M. A., IGBINOBA, P. O., Simons, A. L., & Aghimien, M. O. (2026) · Oncology Reviews · doi:10.3389/or.2026.1814540 · Cited by 1
CAF enhances pancreatic cancer EMT and chemo-resistance
Zhang, S., Ceng, Q., & Liu, M. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2026-0104
Blocking L-carnitine synthesis by meldonium prolongs the survival in mice with pancreatic cancer
Sano, M., Ijichi, H., Tabata, S., Hirayama, A., Shimma, S., Masugi, Y., Ichimaru, Y., Kim, J., Kimura, G., Miyabayashi, K., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117071
Self-citationLeveraging Microphysiological Systems to Facilitate Neutrophil‐Based Cancer Immunotherapy
Shao, S., Diehl, M. I., & Jones, C. N. (2026) · Advanced Science · doi:10.1002/advs.77572
Metastatic pancreatic cancer: from human disease to preclinical modelling
Min, J., Liaki, V., Yu, P. Y., Guerra, C., & Maitra, A. (2026) · Gut · doi:10.1136/gutjnl-2025-336334
Metadata
- Authors
- Ijichi, H., Chytil, A., Gorska, A. E., Aakre, M. E., Bierie, B., Tada, M., Mohri, D., Miyabayashi, K., Asaoka, Y., Maeda, S., Ikenoue, T., Tateishi, K., Wright, C. V. E., Koike, K., Omata, M., & Moses, H. L.
- Affiliations
- The University of Tokyo (JP)
- Vanderbilt University (US)
- Whitehead Institute for Biomedical Research (US)
- Chiba University (JP)
- Yokohama City University (JP)
- Institute of Medical Science, The University of Tokyo (JP)
- Yamanashi Prefectural Central Hospital (JP)
- Corresponding author
- Ijichi, Hideaki
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2011-10-03
- Volume
- 121
- Issue
- 10
- Pages
- 4106-4117
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3195452
- OpenAlex
- W2014434319
- Cited by
- 256
- References
- 50
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 8 · 2023: 9 · 2022: 13 · 2021: 31 · 2020: 19 · 2019: 17 · 2018: 7 · 2017: 20 · 2016: 20 · 2015: 20 · 2014: 22 · 2013: 27 · 2012: 24
- FWCI
- 11.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- Funders
- Vanderbilt University
- Ministry of Education, Culture, Sports, Science and Technology
- Foundation for Promotion of Cancer Research
- National Institutes of Health
- U.S. Public Health Service (U54126505)
- Japan Society for the Promotion of Science (23591011, 22501004)
- National Cancer Institute (CA 085492, R01CA085492, CA102162, R01CA102162)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Connective Tissue Growth Factor Research
- Keywords
- pancreatic ductal adenocarcinoma, tumor-stroma interactions, connective tissue growth factor, CXCR2, CXCL chemokines, desmoplasia, TGFBR2, tumor angiogenesis, tumor growth, overall survival, pancreatic intraepithelial neoplasia
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type II, Animals, Female, Humans, Mice, Inbred C57BL, Mice, Nude, Pancreatic Neoplasms, Signal Transduction, Gene Expression, Proto-Oncogene Proteins p21(ras), Stromal Cells, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Mice, Knockout, Chemokines, CXC, Carcinoma, Pancreatic Ductal, Receptors, Interleukin-8B, Mice, Connective Tissue Growth Factor, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
